Agios Pharmaceuticals COO John Duncan Higgons Unloads 7,000 Shares (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) COO John Duncan Higgons sold 7,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $34.47, for a total value of $241,290.00. Following the completion of the sale, the chief operating officer now directly owns 193,090 shares in the company, valued at approximately $6,655,812. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Agios Pharmaceuticals (NASDAQ:AGIO) traded up 4.65% on Wednesday, hitting $38.47. The stock had a trading volume of 276,580 shares. Agios Pharmaceuticals has a 52 week low of $15.77 and a 52 week high of $49.79. The stock’s 50-day moving average is $38.16 and its 200-day moving average is $32.28. The company’s market cap is $1.306 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $0.01. Analysts expect that Agios Pharmaceuticals will post $-1.47 EPS for the current fiscal year.
AGIO has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. Finally, analysts at JPMorgan Chase & Co. upgraded shares of Agios Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday, April 7th. They now have a $55.00 price target on the stock, up previously from $40.00. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $50.45.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.